BRPI0518949A2 - composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica - Google Patents
composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊuticaInfo
- Publication number
- BRPI0518949A2 BRPI0518949A2 BRPI0518949-7A BRPI0518949A BRPI0518949A2 BR PI0518949 A2 BRPI0518949 A2 BR PI0518949A2 BR PI0518949 A BRPI0518949 A BR PI0518949A BR PI0518949 A2 BRPI0518949 A2 BR PI0518949A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- smoking cessation
- inducing smoking
- inducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPOSTO, USO DE UM COMPOSTO, MÉTODO PARA INDUÇçO DA INTERRUPÇçO DO HABITO DE FUMAR, COMPOSIÇçO FARMACÊUTICA, E, USO DE UMA COMPOSIÇçO FARMACÊUTICA. Ligantes de receptor acetileolina da fórmula I em que A, Ar¹ e Ar² são como descritos nesta especificação, diastereoisômeros, enanciômeros, sais farmaceuticamente aceitáveis dos mesmos, métodos de produção, composições farmacêuticas contendo e métodos para uso dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63636204P | 2004-12-15 | 2004-12-15 | |
US64331905P | 2005-01-12 | 2005-01-12 | |
PCT/SE2005/001909 WO2006065209A1 (en) | 2004-12-15 | 2005-12-13 | Nicotinic acetylcholine receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518949A2 true BRPI0518949A2 (pt) | 2008-12-16 |
Family
ID=36588165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518949-7A BRPI0518949A2 (pt) | 2004-12-15 | 2005-12-13 | composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080113983A1 (pt) |
EP (1) | EP1831231A1 (pt) |
JP (1) | JP2008524208A (pt) |
KR (1) | KR20070090922A (pt) |
AU (1) | AU2005317280A1 (pt) |
BR (1) | BRPI0518949A2 (pt) |
CA (1) | CA2591430A1 (pt) |
IL (1) | IL183603A0 (pt) |
MX (1) | MX2007006743A (pt) |
NO (1) | NO20073551L (pt) |
WO (1) | WO2006065209A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
DE102008015032A1 (de) * | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
DE102008062863A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung |
DE102008062878A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte Furancarboxamide und ihre Verwendung |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
IN2012DN02679A (pt) | 2009-10-12 | 2015-09-04 | Bayer Cropscience Ag | |
US8507516B2 (en) | 2009-10-28 | 2013-08-13 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
CA2779177C (en) * | 2009-10-29 | 2016-08-30 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
WO2011137313A1 (en) | 2010-04-30 | 2011-11-03 | Bristol-Myers Squibb Company | Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
AU2011261164A1 (en) * | 2010-06-01 | 2012-12-13 | The University Of Queensland | Haematopoietic-prostaglandin D2 synthase inhibitors |
JP5714745B2 (ja) * | 2014-04-28 | 2015-05-07 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855290A (en) * | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
DK0777671T3 (da) * | 1994-08-24 | 2000-07-24 | Astrazeneca Ab | Spiro-azabicykliske forbindelser |
AU2001241056A1 (en) * | 2000-03-09 | 2001-09-17 | Mitsubishi Pharma Corporation | Spiro compounds, process for preparing the same and use thereof as drugs |
FR2809732B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
JP2007516200A (ja) * | 2003-07-08 | 2007-06-21 | アストラゼネカ・アクチエボラーグ | α7ニコチン性アセチルコリン受容体に親和性を有するスピロ[1−アザビシクロ[2,2,2]オクタン−3,5’−オキサゾリジン]−2’−オン誘導体 |
-
2005
- 2005-12-13 MX MX2007006743A patent/MX2007006743A/es not_active Application Discontinuation
- 2005-12-13 WO PCT/SE2005/001909 patent/WO2006065209A1/en active Application Filing
- 2005-12-13 KR KR1020077013375A patent/KR20070090922A/ko not_active Application Discontinuation
- 2005-12-13 US US11/721,481 patent/US20080113983A1/en not_active Abandoned
- 2005-12-13 JP JP2007546605A patent/JP2008524208A/ja active Pending
- 2005-12-13 BR BRPI0518949-7A patent/BRPI0518949A2/pt not_active IP Right Cessation
- 2005-12-13 EP EP05819091A patent/EP1831231A1/en not_active Withdrawn
- 2005-12-13 CA CA002591430A patent/CA2591430A1/en not_active Abandoned
- 2005-12-13 AU AU2005317280A patent/AU2005317280A1/en not_active Abandoned
-
2007
- 2007-05-31 IL IL183603A patent/IL183603A0/en unknown
- 2007-07-09 NO NO20073551A patent/NO20073551L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20073551L (no) | 2007-08-01 |
MX2007006743A (es) | 2007-07-09 |
IL183603A0 (en) | 2007-09-20 |
JP2008524208A (ja) | 2008-07-10 |
US20080113983A1 (en) | 2008-05-15 |
KR20070090922A (ko) | 2007-09-06 |
EP1831231A1 (en) | 2007-09-12 |
AU2005317280A1 (en) | 2006-06-22 |
WO2006065209A1 (en) | 2006-06-22 |
CA2591430A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0518949A2 (pt) | composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica | |
BRPI0511531A (pt) | composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto | |
BRPI0610359B8 (pt) | compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis | |
BRPI0511532A (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto | |
BRPI0513672A (pt) | processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol | |
CY1116554T1 (el) | Αλατα κλοπιδογρελης και μεθοδος παρασκευης | |
BRPI0510719A (pt) | derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos | |
DK1934174T3 (da) | Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
BRPI0809011A8 (pt) | composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única | |
BRPI0507198A (pt) | derivados de bisariluréia | |
DK1797088T3 (da) | Hidtil ukendte chromen-2-on-derivater og anvendelse heraf som monoamin-neurotransmitter-genoptagelseshæmmere | |
BRPI0618479A2 (pt) | pirrolpiridinas composição farmacêutica que as contém | |
EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
BRPI0616077B8 (pt) | composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos | |
NO20090175L (no) | Stabile laquinimod sammensetninger | |
CY1112828T1 (el) | Ενωσεις αναστολης της μιτωτικης διαδικασιας | |
BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
ECSP088971A (es) | Ligandos 101 de los receptores nicotínicos de acetilcolina | |
ATE490958T1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
DE602005021150D1 (de) | 3-substituierte pyridinderivate als h3-antagonisten | |
MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
WO2005123679A3 (en) | Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |